Diligence memo · auto-generated · as of July 2, 2026
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Bright Peak Therapeutics, Inc. operates in Pharma, based in Del Mar.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Bright Peak Therapeutics, Inc. has raised $197M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $107M on 2021-05-14.
Most recent recorded round closed around 2024-05-07.
Valuation (modeled)modeled
Provath models Bright Peak Therapeutics, Inc. at approximately $1.0B (range $428M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.49× the median modeled value of Series D+ Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 36 months.
Last raise 2.2 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharma peers (310 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Mirador Therapeutics, Inc., Autolus Therapeutics plc, Candid Therapeutics, Inc., Bluejay Therapeutics, Inc., Halda Therapeutics, LLC.
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.